|
|
|
| Wockhardt, Sun get US okay for generic drug | 19-NOV-09 |
|
| Indian drug companies Wockhardt and Sun Pharmaceutical Industries have received final approval from the United States Food and Drug Administration (USFDA) to market generic versions of Nicardipine, the hypertension drug. |
|
|
|
| Model N to invest Rs 37cr | 19-NOV-09 |
|
| The company has, so far, invested $3.8 million (about Rs 17.48 crore) in India, said Zack Rinat, founder and chief operating officer. Globally, the company will invest $120 million (Rs 555 crore) during this financial year. |
|
|
|
| Wockhardt gets FDA nod for Nicardipine injections | 18-NOV-09 |
|
| Drug firm Wockhardt today said it has received the final approval from the US Food and Drug Administration (FDA) for marketing Nicardipine HCI injections in 25mg/10 ml strength, used in the treatment of hypertension. |
|
|
|
|
|
|
| India Inc discovers the power of two | 18-NOV-09 |
|
| When US-based drug major Merck bought Schering-Plough early this month, it decided to go off the beaten track. Instead of having one managing director (MD) for the merged entity, it decided to retain both: Naveen A Rao will continue to head Merck’s subsidiary MSD Pharmaceuticals in India and K G Ananthakrishnan will retain his position as MD of Schering-Plough’s subsidiary Fulford India. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Torrent Pharma ends in red despite a firm start | 16-NOV-09 |
|
| Torrent Pharma slipped into red to a low of Rs 377, down almost 7% from the day's high of Rs 405. The stock finally ended with a loss of 2.7% at Rs 382. The counter registered trades of around 36,500 shares on the BSE. |
|
|
|
|
|
|
| Glenmark settles patent dispute with Medicis | 16-NOV-09 |
|
| Pharma firm Glenmark today said it has settled all pending patent disputes with US-based Medicis Pharmaceutical Corp over a skin disease drug, besides signing a licensing agreement for new drug delivery system (NDDS). |
|
|
|
|
|
|
| Novo Nordisk eyes India as insulin hub for sub-continent | 16-NOV-09 |
|
| Denmark-based world leader in diabetes care Novo Nordisk can look at making India the hub for manufacturing insulin for the sub-continent. The company today inaugurated a dedicated facility with a capacity of 26 million vials per annum in partnership with Ahmedabad based Torrent Pharmaceuticals Ltd. Torrent has been manufacturing insulin for Novo Nordisk since the early nineties. |
|
|
|
Content Guide
